CROXHIGH SIGNALFINANCIAL10-K

Crocs reported a dramatic decline in operating income alongside significant deterioration across multiple financial metrics, signaling potential operational challenges.

The substantial drop in operating profitability combined with declining cash flows and reduced stockholders' equity suggests meaningful headwinds affecting the company's core business performance. While the company continues to articulate growth strategies around product diversification and international expansion, the financial results indicate execution challenges that warrant close investor scrutiny.

Comparing 2026-02-12 vs 2025-02-13View on EDGAR →
FINANCIAL ANALYSIS

Crocs experienced a severe deterioration in profitability with operating income collapsing, while operating cash flow declined meaningfully to $710.4M. The company's balance sheet also weakened notably, with stockholders' equity falling to $1.3B and total assets declining 13.2% to $4.2B, though debt reduction and lower capital expenditures provide some offsetting positives. The overall financial picture suggests significant operational challenges despite management's continued focus on strategic growth initiatives.

FINANCIAL STATEMENT CHANGES
Operating Income
P&L
-85.4%
$1.0B→$149.5M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Debt
Balance Sheet
-30.6%
$16.8M→$11.6M

Debt reduced 30.6% — deleveraging strengthens balance sheet and reduces financial risk.

Stockholders Equity
Balance Sheet
-29.5%
$1.8B→$1.3B

Equity decreased 29.5% — buybacks or losses reducing book value, monitor solvency ratios.

Operating Cash Flow
Cash Flow
-28.4%
$992.5M→$710.4M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Cash & Equivalents
Balance Sheet
-27.8%
$180.5M→$130.4M

Cash decreased 27.8% — monitor burn rate and upcoming capital needs.

Capital Expenditure
Cash Flow
-26.1%
$69.3M→$51.2M

Capex reduced 26.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

R&D Expense
P&L
+15.6%
$25.6M→$29.6M

R&D investment increased 15.6% — signals commitment to future product development, though near-term margin impact.

Total Assets
Balance Sheet
-13.2%
$4.8B→$4.2B

Total assets contracted 13.2% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-12
PRIOR — 2025-02-13
ADDED
The HEYDUDE Brand provides opportunity to play in a broader casual footwear market.
Expand wearing occasions through thoughtful diversification of our product range to attract new and retain existing consumers For the Crocs Brand, we see opportunity to diversify within our clog, sandal, personalization, and broader lifestyle product offering, ultimately attracting new consumers.
We believe sandals are a natural extension of the Crocs Brand leveraging our signature molding technology to provide casual, comfortable footwear for a variety of wearing occasions and consumers.
In addition to the development of our sandals product pillar, we see further opportunity to build on a broader personalization opportunity while expanding into more lifestyle occasions.
Diversification within our icon silhouettes include the Stretch Sox, Stretch Canvas, Craft Linen, and Stretch Jersey.
+7 more — sign up free →
REMOVED
On February 17, 2022 (the Acquisition Date ), we acquired (the Acquisition ) 100% of the equity of a privately-owned casual footwear brand business ( HEYDUDE ).
HEYDUDE is engaged in the business of distributing and selling casual footwear under the brand name HEYDUDE.
The majority of HEYDUDE sales are currently in the United States.
To that end, in 2024, we continued our message of Come As You Are for the Crocs Brand and the slogan Good To Go-To for the HEYDUDE Brand.
The addition of the HEYDUDE Brand to our portfolio provides opportunity to play in a broader casual footwear market.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →